Aravive Investor Presentation Deck
Dedicated to Developing Innovative Treatments for
Life-Threatening Diseases to Increase Patient Survival
Batiraxcept development program focused on difficult-to-treat cancers with high unmet medical
needs
Proprietary, differentiated first-in-class therapeutic targeting and inhibiting GAS6/AXL signaling;
GAS6/AXL is associated with tumor growth, metastasis, drug resistance, and poor survival rates
Batiraxcept has potential in multiple indications and multiple therapeutic combinations
Ongoing Phase 3 trial to treat patients with platinum resistant ovarian cancer; top line data
expected mid 2023 and BLA could be submitted end of 2023
Ongoing Phase 1b/2 trial to treat patients with clear cell renal cell carcinoma; registrational study
using biomarker for potential accelerated approval agreed with FDA
Ongoing Phase 1b trial as first-line therapy for pancreatic cancer
38View entire presentation